Nachrichten

Baylis Medical announced today the first Arctic Front™ Advance Cryoballoon procedures performed using the VersaCross Transseptal Solution. The VersaCross solution is the world’s first all-in-one left-heart access device featuring an atraumatic RF-tipped wire, which acts as both puncture device and exchange rail. The puncture wire features Baylis’ signature RF puncture technology, which facilitates controlled and precise transseptal procedures.

A randomized controlled trial has found that use of Baylis Medical’s NRG® Transseptal Needle results in shorter time in achieving transseptal access, less transseptal attempts, and reduced exposure to radiation, compared to use of a conventional transseptal needle.

Baylis Medical announced today key activities that will be featured at Transcatheter Cardiovascular Therapeutics (TCT) 2019, the Cardiovascular Research Foundation’s 31st annual conference and premier interventional cardiovascular medicine educational meeting, in San Francisco, CA from September 25-29.

A cost-effectiveness analysis completed by the University of California, San Francisco (UCSF) and Baylis Medical has shown that use of Baylis’ RF transseptal needle results in cost savings per procedure, compared to use of a mechanical transseptal needle.

For the second year in a row, Baylis Medical has won the Canada’s Best Managed Companies designation.

Baylis Medical is pleased to announce that seasoned marketing executive Gloria Yee has joined Baylis as its Vice President of Marketing. In her role, Gloria will be instrumental in expanding the company’s global commercialization strategy.